Latest Breaking News On - செயல்பாடுகள் தகவல் - Page 1 : comparemela.com

Published: May 10, 2021 NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2021. “We continued to make significant strides in the quarter toward becoming a premier biopharmaceutical company focused on delivering potentially life-changing medicines to people living with serious CNS conditions. We successfully filed our NDA for AXS-05 for the treatment of MDD with the FDA, which was granted Priority Review, and are on track to file our NDA for AXS-07 for the acute treatment of migraine this quarter,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “Pre-commercial activities are intensifying as planned to ensure launch readiness assuming FDA approval. The rest of our pipeline continues to progress with the anticipated initiation of the plann

New yorkUnited statesHerriot tabuteauMark jacobsonCenters for diseaseAxsome therapeutics incInternational society for pharmacoeconomicsDrug administrationMental health americaOutcomes researchAmerican society for clinical psychopharmacologyMental health monthAmerican headache societyBofa health care conferenceDuke universityPriority review